Hofseth BioCare Trial Shows OmeGo Outperforms Higher-Dose Omega-3 Rival

Hofseth Biocare ASA ( (HOFBF) ) has provided an announcement.

Hofseth BioCare’s OmeGo, a patented full-spectrum salmon oil, has demonstrated strong clinical performance in a head-to-head trial against a popular omega-3 supplement. Despite containing 2.5 times less EPA and DHA, OmeGo increased participants’ Omega-3 Index by more than 70% over 14 weeks and was markedly more effective at reducing key inflammatory markers associated with chronic disease.

The findings suggest that OmeGo’s natural food matrix and full-spectrum fatty acid profile significantly enhance bioavailability and more closely replicate the health benefits of eating fish. This outcome challenges the prevailing industry assumption that higher-dose concentrated fish oils are inherently superior, potentially reshaping competitive dynamics and product positioning in the nutraceuticals omega-3 market.

More about Hofseth Biocare ASA

Hofseth BioCare ASA is a Norwegian consumer and pet health company that upcycles side streams from the salmon industry into high-value nutritional ingredients. Its portfolio includes ProGo bioactive peptides and collagen, OmeGo whole salmon oil, and CalGo/NT-II salmon bone powder for bone and joint health, all developed with a strong focus on sustainability, scientific validation, and patented health benefits.

The company’s products target human and pet wellness areas such as iron metabolism, weight management via GLP-1 receptor activation, immune and respiratory health, and healthy ageing. Hofseth BioCare has also spun out HBC Immunology to pursue therapeutic applications in oncology and asthma, and it operates from headquarters in Ålesund with international branches, while being listed on the Oslo Stock Exchange under the ticker HBC.

Average Trading Volume: 110,765

Current Market Cap: NOK585.8M

See more insights into HOFBF stock on TipRanks’ Stock Analysis page.